Mid-size and generic companies face unique hurdles in the ever-evolving pharmacovigilance landscape.

Mid-size companies often need to balance accountability for pharmacovigilance activities with strategic priorities like managing affiliate networks, maintaining centralized operations, and safeguarding trust and reputation. Tackling these challenges requires comprehensive solutions that span tactical, compliance, and strategic support, especially for established brands, over-the-counter (OTC) products, and Pharma Plus offerings.

For generic companies, the focus shifts to cost control and minimizing the loss of value from full-time equivalents (FTEs). Key concerns include maintaining accountability in post-commercialization activities, ensuring compliance to mitigate high-risk volumes, and managing distribution networks. Additionally, decisions about centralizing operations or managing affiliates often demand careful planning to uphold market reputation and trust.

Both mid-size and generic companies are grappling with high costs, resource constraints, and the challenge of adapting quickly to new regulations. Streamlining processes, reducing time-to-market, and ensuring compliance under these pressures require strategic, customized solutions.

QbD Group’s vigilance services are designed to address these challenges head-on, offering tailored support to help businesses thrive in this complex environment.